5 companies from Northern Ireland participated in BIO Digital 2020.
Northern Ireland has a thriving life and health sciences sector offering expertise across a range of specialisms, including precision medicine, clinical trials and digital health. Northern Ireland also has clinical specialisms within the areas of oncology, cardiology, ophthalmology, respiratory and diabetes.
The sector includes global companies such as Almac, Randox, Norbrook, Bemis Healthcare, Actavis and Terumo. These businesses, which are a mix of international investors and indigenous companies continue to grow and prosper in the region – testament to Northern Ireland’s compelling proposition. Companies operating in the region benefit from access to an exceptionally skilled workforce, competitive operating costs, a pro-business environment, a sophisticated infrastructure and an existing cluster of synergistic businesses.
The region is home to internationally recognised universities, Queen’s University Belfast and Ulster University. Queen’s is a member of the Russell Group of the UK’s leading research intensive universities and Ulster University is one of the top 5 universities in the UK for world-leading research in biomedical sciences.
Northern Ireland’s Life & Health Sciences sector is renowned for housing some of the world’s most innovative companies in leading diagnostics. Following the World Health Organisation’s recommendation for the urgent need for testing, Northern Ireland companies including Randox, BioPanda Reagents and Fortress Diagnostics are rising to the challenge to develop fast tracking testing methods for the detection of COVID-19.
Invest Northern Ireland (Invest NI) is the economic development agency for this part of the UK. It promotes inward investment and trade with Northern Ireland from an extensive network of overseas offices, including its Americas HQ located in Boston.
Almac Group Limited
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. It is proud to be supporting 34 separate crucial research projects to help find a treatment for COVID-19.
Exploristics is a world-leading provider of biosimulation software and biostatistics services for designing, analysing, and reporting clinical trials and real-world studies. Our unique approach transforms clinical development through our study design platform, KerusCloud, and specialist consultancy services.
Fusion Antibodies increase the pace to the clinic for biotechnology and pharmaceutical organisations through services in antibody discovery, engineering and supply. Fusion enables clients to develop the best possible antibodies against their target, getting them closer to their end-goal; the provision of treatments that improve the lives of patients throughout the world.
pHion Therapeutics is a therapeutic vaccine development company, spun out of Queen’s University Belfast.
pHion is utilising its patented peptide-based drug delivery system (DDS) termed RALA that, when combined with mRNA, generates a uniquely potent therapeutic CD8+ response, without provoking an innate immune response.
ProAxsis has utilised its patented ProteaseTag technology to develop assays measuring active protease disease biomarkers, including neutrophil elastase and proteinase 3, associated with chronic respiratory diseases such as COPD.